ABVX
Price
$6.05
Change
+$0.16 (+2.72%)
Updated
Apr 2 closing price
Capitalization
394.46M
60 days until earnings call
PHAT
Price
$5.49
Change
+$0.37 (+7.23%)
Updated
Apr 2 closing price
Capitalization
382.31M
40 days until earnings call
Ad is loading...

ABVX vs PHAT

Header iconABVX vs PHAT Comparison
Open Charts ABVX vs PHATBanner chart's image
Abivax SA
Price$6.05
Change+$0.16 (+2.72%)
Volume$130.97K
Capitalization394.46M
Phathom Pharmaceuticals
Price$5.49
Change+$0.37 (+7.23%)
Volume$2.75M
Capitalization382.31M
ABVX vs PHAT Comparison Chart
Loading...
ABVX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABVX vs. PHAT commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABVX is a StrongBuy and PHAT is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (ABVX: $6.05 vs. PHAT: $5.49)
Brand notoriety: ABVX and PHAT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABVX: 57% vs. PHAT: 206%
Market capitalization -- ABVX: $394.46M vs. PHAT: $382.31M
ABVX [@Biotechnology] is valued at $394.46M. PHAT’s [@Biotechnology] market capitalization is $382.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABVX’s FA Score shows that 0 FA rating(s) are green whilePHAT’s FA Score has 0 green FA rating(s).

  • ABVX’s FA Score: 0 green, 5 red.
  • PHAT’s FA Score: 0 green, 5 red.
According to our system of comparison, both ABVX and PHAT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABVX’s TA Score shows that 5 TA indicator(s) are bullish while PHAT’s TA Score has 4 bullish TA indicator(s).

  • ABVX’s TA Score: 5 bullish, 5 bearish.
  • PHAT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ABVX is a better buy in the short-term than PHAT.

Price Growth

ABVX (@Biotechnology) experienced а -14.67% price change this week, while PHAT (@Biotechnology) price change was -14.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.26%. For the same industry, the average monthly price growth was -7.43%, and the average quarterly price growth was -11.99%.

Reported Earning Dates

ABVX is expected to report earnings on Jun 02, 2025.

PHAT is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-5.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABVX($394M) and PHAT($382M) have the same market capitalization . ABVX YTD gains are higher at: -17.350 vs. PHAT (-32.389).
ABVXPHATABVX / PHAT
Capitalization394M382M103%
EBITDAN/A-261.52M-
Gain YTD-17.350-32.38954%
P/E RatioN/AN/A-
RevenueN/A55.3M-
Total CashN/A297M-
Total DebtN/A202M-
TECHNICAL ANALYSIS
Technical Analysis
ABVXPHAT
RSI
ODDS (%)
Bearish Trend 1 day ago
67%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 13 days ago
82%
Bullish Trend 14 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Ad is loading...
ABVX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SCVEX19.39N/A
N/A
Hartford Schroders International Stk A
POSIX9.33N/A
N/A
Principal Global Real Estate Sec Instl
FNARX45.87N/A
N/A
Fidelity Natural Resources Fund
GINNX55.13N/A
N/A
Guinness Atkinson™ Global Inntrs Instl
MSJCX15.18N/A
N/A
Morgan Stanley Global Endurance C

ABVX and

Correlation & Price change

A.I.dvisor tells us that ABVX and PHAT have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ABVX and PHAT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABVX
1D Price
Change %
ABVX100%
+2.72%
PHAT - ABVX
31%
Poorly correlated
+7.23%
ZYME - ABVX
29%
Poorly correlated
+2.58%
RGNX - ABVX
28%
Poorly correlated
+4.29%
INZY - ABVX
28%
Poorly correlated
+6.48%
IDYA - ABVX
28%
Poorly correlated
+10.70%
More